Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug induced interstitial lung disease in oncology phase I trials.
Yonemori K, Hirakawa A, Kawachi A, Kinoshita F, Okuma H, Nishikawa T, Tamura K, Fujiwara Y, Takebe N. Yonemori K, et al. Cancer Sci. 2016 Dec;107(12):1830-1836. doi: 10.1111/cas.13087. Cancer Sci. 2016. PMID: 27685762 Free PMC article.
64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.
Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K. Sasada S, et al. Among authors: yonemori k. Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227. Ann Oncol. 2017. PMID: 28505219 Free article. No abstract available.
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Nishikawa T, et al. Among authors: yonemori k. Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5. Cancer Sci. 2017. PMID: 28665051 Free PMC article. Clinical Trial.
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.
Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K. Bun S, et al. Among authors: yonemori k. Invest New Drugs. 2018 Feb;36(1):151-155. doi: 10.1007/s10637-017-0487-3. Epub 2017 Jul 21. Invest New Drugs. 2018. PMID: 28733700 Clinical Trial.
348 results